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ABSTRACT
Objective This was a post hoc analysis of the 
Edaravone Phase III Study MCI186-19 (’Study 19’) to 
examine the utility of clinical staging systems as end 
points in clinical trials in amyotrophic lateral sclerosis 
(ALS).
Methods Amyotrophic Lateral Sclerosis Functional 
Rating Scale—Revised item scores from Study 19 
were retrospectively mapped to King’s stage and 
Milano- Torino staging (MiToS) stage. We assessed the 
percentage of patients who experienced progression 
in King’s and MiToS stages during Study 19. We also 
assessed disease progression in subgroups of patients 
according to baseline King’s stage.
Results During double- blind treatment, the percentage 
of patients who experienced a progression in King’s 
stage was lower for edaravone (42.0%, 95% CI 30.4% 
to 53.6%) than placebo (55.9%, 95% CI 44.1% to 
67.6%). The most pronounced effect was noted among 
patients who were in stage 1 and was maintained 
throughout open- label treatment. An analysis of a 
≥2- stage progression in MiToS stage showed no 
difference between treatment arms during double- blind 
treatment, but during the open- label period, more rapid 
progression was noted among patients in the placebo–
edaravone arm than among those in the edaravone–
edaravone arm (log- rank test, p<0.001).
Conclusions The King’s and MiToS staging systems 
provided utility in assessing clinical progression in 
Edaravone Study 19. These findings may support the use 
of staging systems as end points in ALS clinical trials 
and to understand the timing of benefit as measured by 
these scales.
INTRODUCTION
Clinical staging systems have proven valuable in a 
variety of neurological diseases, including Parkin-
son’s disease, multiple sclerosis and Alzheimer’s 
disease.1–4 In amyotrophic lateral sclerosis (ALS), 
most clinical studies have relied on change from 
baseline in the total Amyotrophic Lateral Sclerosis 
Functional Rating Scale—Revised (ALSFRS- R) 
score as the primary end point. Although func-
tional rating scales such as the ALSFRS- R are useful 
measures in clinical trials for assessing change in a 
patient’s clinical status, they may not place suffi-
cient emphasis on important milestones in disease 
progression. ALS clinical staging systems potentially 
could provide useful adjunctive information.
The King’s ALS clinical staging system assesses 
anatomical spread of ALS, based on the number 
of affected regions (bulbar, upper limb and lower 
limb) and includes advanced stages defined by 
nutritional or respiratory failure.5 6 The Milano- 
Torino staging (MiToS) system assesses the number 
of functional domains in which there is a loss of 
independent function.7 The domains in the MiToS 
system include movement (walking/self- care), swal-
lowing, communicating, and breathing.7 The King’s 
and MiToS systems have demonstrated utility in a 
variety of settings. For example, retrospective anal-
yses indicate that riluzole prolongs King’s stages 1 
and 4, and MiToS stage 1.8 9
Two therapies—riluzole and edaravone—have 
been approved for treating ALS in several coun-
tries.10 11 Edaravone (Radicava; Mitsubishi Tanabe 
Pharma America, New Jersey, USA) has been shown 
in a clinical trial to slow the rate of functional loss, 
as measured by the ALSFRS- R.12 Based on the 
results of the pivotal phase III study for edaravone 
(Edaravone Phase III Study MCI186-19 (Study 
19)), the drug has been approved for use in patients 
with ALS in Japan, South Korea, USA, Canada 
and Switzerland. However, countries and regions 
have differing opinions and requirements for drug 
approval (eg, edaravone is not yet approved in the 
European Union), which has sparked debate and 
differing viewpoints on edaravone. The King’s and 
MiToS staging systems were not available at the 
time Edaravone Study 19 was being planned and 
thus were not included as measures.
In order to help assess the value of clinical staging 
systems as end points in randomised controlled 
trials in ALS, we conducted a post hoc analysis of 
Study 19 with respect to progression in clinical 
staging, using both the King and MiToS systems.
METHODS
Study 19 study design
Study 19 was a randomised, double- blind, parallel- 
group, placebo- controlled study conducted in 
Japan; details of the study and prespecified analyses 
of data from the 24- week double- blind treatment 
period and the 24- week open- label active- treatment 
extension have been previously reported ( clinical-
trials. org: NCT01492686).12 13 The study design 
for Study 19 incorporated an enrichment strategy 
based on key learnings from a previous phase III 
study (MCI186-16, Study 16) to increase the ability 
of the trial to detect a significant effect of treatment 
with the ALSFRS- R within a 6- month time frame.
Eligible participants were aged 20–75 years, 
with ALS grade 1 or 2 on the Japan ALS Severity 
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Classification, scores of ≥2 on all 12 items of the ALSFRS- R, 
forced vital capacity of ≥80%, definite or probable ALS 
according to the El Escorial and revised Airlie House criteria, and 
duration of disease from the first symptom (any ALS symptom) 
for <2 years. Patients were ineligible if they had scores of ≤3 
on ALSFRS- R items for dyspnoea, orthopnoea or respiratory 
insufficiency; other exclusion criteria included a history of spinal 
surgery after onset of ALS or creatinine clearance of 50 mL/
min or less. Initiation of riluzole after the start of the obser-
vation period was prohibited; however, patients receiving rilu-
zole at study entry could continue to do so during the trial at 
an unchanged dose. Criteria for study discontinuation included 
patient request, ineligibility for the study, adverse event, require-
ment for tracheotomy, requirement for respiratory support all 
day long and worsening of ALS.
Briefly, after a 12- week observation period, eligible patients 
(those with a decrease of 1–4 points in the ALSFRS- R score 
during this period) were randomly assigned 1:1 to receive 6 
cycles of edaravone therapy or placebo over 24 weeks. At the end 
of the double- blind treatment, all patients could receive open- 
label treatment with edaravone for another 24 weeks (cycles 
7–12). Edaravone was administered in a 60 mg dose, once a day, 
via intravenous infusion over 60 min. Infusion was given for 14 
days for the first treatment cycle and for 10 days in the 14- day 
treatment period for all subsequent cycles. Each treatment cycle 
was followed by a 14- day drug- free period.
The primary efficacy end point of the study was the change in 
ALSFRS- R score from baseline to the end of week 24.
Study 19 patients
In total, 137 patients were randomised to receive either edara-
vone (n=69) or placebo (n=68) in Study 19. Baseline charac-
teristics of patients were well balanced between the 2 treatment 
groups, except for male sex and ALS severity (table 1).12 13 A 
total of 127 patients completed double- blind treatment; 2 
patients receiving edaravone and 8 patients receiving placebo 
discontinued treatment, principally due to disease progression. A 
total of 123 patients were enrolled in the open- label extension: 
65 patients from the edaravone group (edaravone–edaravone) 
and 58 patients from the placebo group (placebo–edaravone); 
53 and 40 of these patients, respectively, completed open- label 
treatment. At week 48 (ie, the end of the open- label extension), 
the discontinuation rate was 23% for patients initially assigned 
to receive edaravone and 41% for patients initially assigned to 
receive placebo.
Post hoc staging analyses
ALSFRS- R item responses in Study 19 were retrospectively 
mapped to King’s stage and MiToS stage as previously described.6 7 
Mapping of ALSFRS- R item responses to clinical staging systems 
makes it more likely that a patient will experience an event before 
being lost to follow- up, because an event constitutes patterns of 







  Men 38 (55) 41 (60)
  Women 31 (45) 27 (40)
Mean age (years) (SD) 60.5 (10) 60.1 (10)
Mean duration of disease (years) (SD) 1.13 (0.5) 1.06 (0.5)
Initial symptom, n (%)
  Bulbar symptom 16 (23) 14 (21)
  Limb symptom 53 (77) 54 (79)
ALS diagnostic criteria, n (%)*
  Definite 28 (41) 27 (40)
  Probable 41 (59) 41 (60)
ALS severity, n (%)†
  Grade 1 22 (32) 16 (24)
  Grade 2 47 (68) 52 (76)
Mean ALSFRS- R score (SD)
  Before observation period 43.6 (2.2) 43.5 (2.2)
  Baseline (end of 12 weeks of observation) 41.9 (2.4) 41.8 (2.2)
Concomitant riluzole, n (%) 63 (91) 62 (91)





ALS severity, n (%)†
  Grade 1 8 (12.3) 5 (8.6)
  Grade 2 27 (41.5) 22 (37.9)
  Grade 3 21 (32.3) 24 (41.4)
  Grade 4 9 (13.8) 7 (12.1)
Mean ALSFRS- R score (SD) 37.8 (4.9) 34.8 (5.8)
*According to revised El Escorial criteria.
†According to Japan ALS severity classification (grades 1–5, with grade 5 being 
most severe).
ALS, amyotrophic lateral sclerosis; ALSFRS- R, Amyotrophic Lateral Sclerosis 
Functional Rating Scale—Revised ; FAS, full analysis set.
Figure 1 King’s and MiToS stages at study entry. Percentages of patients in each treatment arm corresponding to each clinical stage are shown 
(edaravone, blue columns; placebo, yellow columns). ALS, amyotrophic lateral sclerosis; MiToS, Milano- Torino staging.
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change in the ALSFRS- R, and such changes tend to occur rela-
tively frequently. As mentioned in the Introduction section, the 
King’s ALS clinical staging system assesses anatomical spread of 
ALS, based on the number of affected regions (bulbar, upper 
limb and lower limb).5 6 King’s stage 1 consists of functional 
involvement of 1 central nervous system (CNS) region, while 
stages 2 and 3 correspond to functional involvement of 2 and 3 
CNS regions, respectively. Stage 4A represents nutritional failure 
and stage 4B represents significant respiratory failure. Stage 5 
is death. For King’s analysis, ALSFRS- R item responses were 
mapped to King’s staging system based on responses to items 1 
(speech), 2 (salivation), 3 (swallowing), 4 (handwriting), 5A/B 
(self- feeding), 8 (walking), 10 (dyspnoea) and 12 (respiratory 
insufficiency) as previously described. The MiToS system assesses 
the number of functional domains in which there is a loss of 
independent function.7 MiToS stage 0 consists of no functional 
domains lost, while stages 1–4 consist of loss of 1 to 4 func-
tional domains, respectively. Stage 5 is death. MiToS mapping 
was done by mapping ALSFRS- R item responses to the MiToS 
system based on responses to items 1 (speech), 3 (swallowing), 4 
(handwriting), 6 (dressing/hygiene), 8 (walking), 10 (dyspnoea) 
and 12 (respiratory insufficiency).7 Study 19 was not designed to 
detect statistical differences in staging analyses nor were patients 
allocated according to stage.
One limitation of the study was its post hoc nature, since 
this analysis was based directly on the primary end point data 
from the study and simply converts ALSFRS- R score data into 
the 2 staging systems. Because findings were positive for the 
ALSFRS- R, these post hoc analyses would be biased towards a 
positive finding. Study 19, however, was not designed to assess 
effects on clinical staging and was not powered for this end 
point.
The percentages of patients in each treatment group who expe-
rienced a progression in King’s and MiToS stages were examined 
from baseline to the end of cycles 6 and 12. Data are reported as 
point estimates and 95% CI. Kaplan- Meier time- to- event anal-
ysis was used to examine time to first progression in King’s and 
MiToS stages and time to 2- stage progression in MiToS, at which 
point patients lost to follow- up were censored. Log- rank test was 
used to determine the statistical significance of differences in the 
Kaplan- Meier curves between study arms.
Figure 2 Number of patients lost to follow- up. The number of patients lost to follow- up is shown for each assessment. The blue lines represent patients 
receiving edaravone and edaravone–edaravone; the yellow lines represent patients receiving placebo, and the blue dashed lines represent patients receiving 
placebo–edaravone. ALSFRS- R, Amyotrophic Lateral Sclerosis Functional Rating Scale—Revised; MiToS, Milano- Torino staging.
Figure 3 Kaplan- Meier analysis of time to any decline in King’s ALS clinical stage. Kaplan- Meier curves are shown for time to any decline in King’s ALS 
clinical stage for patients in the double- blind period (blue line, edaravone; yellow line, placebo) and in the active- treatment period (blue line, edaravone–
edaravone; dashed blue line, placebo–edaravone). Plus symbols represent patients who were censored from the analysis due to loss to follow- up (a plus 
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A subgroup analysis was conducted by analysing the trends in 
changes from baseline in ALSFRS- R score in patients grouped 
according to King’s stage at baseline. A linear mixed- effects 
model was used to examine the relationship between the trend 
of ALSFRS- R total scores over time and King’s stage at base-
line. A random intercept was assumed, and ALSFRS–R scores at 
baseline were included as covariates for adjustment. Fixed effects 
included treatment, King’s stage at baseline, time since enrol-
ment, and their interaction terms. Trend lines were plotted and 
differences in treatment effect were assessed by a mixed- effects 
model for repeated measures analysis.
RESULTS
King’s and MiToS stages at baseline
Approximately 80% of patients were King’s stage 1 or 2 at study 
entry, and all patients were at MiToS stage 0, as expected based 
on the Study 19 inclusion criteria (figure 1). King’s stage at 
enrolment did not differ notably between the treatment groups.
Loss to follow-up
One of the advantages of using clinical staging systems or 
mapping ALSFRS- R item responses to clinical staging systems 
is that patients may be more likely to experience a progression 
in clinical stage prior to being lost to follow- up, which reduces 
bias due to informative censoring. In this post hoc analysis, most 
patients experienced an event in King’s or MiToS analyses before 
dropping out of the study (figure 2).
In King’s staging analysis through cycle 12, 50 patients in the 
edaravone–edaravone group experienced an event through cycle 
12, with 2 patients censored; in the placebo–edaravone group, 
54 patients experienced an event, with 3 patients censored. In 
the MiToS analysis of time to any progression, through cycle 12, 
in the edaravone–edaravone group, 46 patients experienced an 
event, with 4 patients censored; in the placebo–edaravone group, 
50 patients experienced an event, with 10 patients censored. In 
the MiToS analysis of time to progression by ≥2 stages, through 
cycle 12, in the edaravone–edaravone group, 7 patients experi-
enced an event, with 16 patients censored; in the placebo–edar-
avone group, 16 patients experienced an event, with 20 patients 
censored.
Time to progression in King’s clinical stage
Patients in the placebo arm experienced shorter times to progres-
sion in King’s clinical stage as compared with patients in the 
edaravone arm (figure 3); the difference did not reach statis-
tical significance (log- rank test, p=0.103). Among patients who 
received edaravone during double- blind treatment, fewer expe-
rienced a progression in King’s stage by the end of cycle 6 versus 
those receiving placebo: edaravone, 42.0% (95% CI 30.4% to 
53.6%) vs placebo, 55.9% (95% CI 44.1% to 67.6%).
Patients receiving placebo crossed over to open- label edara-
vone treatment at cycle 7, and by the end of cycle 12, a progres-
sion in King’s stage was experienced by 72.5% (95% CI 62.3% 
to 82.6%) of patients receiving edaravone–edaravone vs 79.4% 
(95% CI 69.1% to 88.2%) of those receiving placebo–edaravone.
King’s stage at which edaravone affects disease progression
The effects of edaravone on King’s clinical stage were also 
assessed by conducting a Kaplan- Meier analysis of patients 
remaining in each King’s clinical stage (figure 4). Edaravone 
treatment appeared to show the most pronounced effect 
in slowing the transition from stage 1 to stage 2, that is, the 
spread of functional involvement of ALS from 1 CNS region to 
2 CNS regions (figure 4A). There may have also been an effect 
in slowing the transition from stage 2 to stage 3, but this was 
less well pronounced than the effect on the stage 1 to stage 
Figure 4 Kaplan- Meier analyses of patients remaining in each King’s 
stage. Kaplan- Meier curves show time to event analyses for proportions of 
patients remaining in King’s stage 1 (A), stage 2 (B), stage 3 (C) or stage 
4 (D). All analyses are for time points during the 24- week double- blind 
treatment period. Plus symbols represent patients who were censored from 
the analysis (a plus symbol may represent more than one patient). The 
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2 transition (figure 4B). There were no discernible effects on 
later transitions in King’s clinical stage by edaravone treatment 
(figure 4C,D).
Time to progression in MiToS clinical stage
Patients in both the placebo and edaravone arms experienced 
similar times to progression in MiToS clinical stage through the 
double- blind period; however, there appeared to be a lower risk 
of progression during the open- label extension among patients 
receiving edaravone–edaravone than among those receiving 
placebo–edaravone (figure 5). At end of cycle 6, the percentage of 
patients experiencing a progression in MiToS stage were compa-
rable: edaravone, 46.4% (95% CI 34.8% to 58.0%) vs placebo, 
47.1% (95% CI 35.3% to 58.8%). During the open‐label phase, 
separation in Kaplan- Meier curves for any progression in MiToS 
stage was noted at the end of cycle 12, although this separation 
was not statistically significant (log- rank test, p=0.308): edara-
vone–edaravone, 66.7% (95% CI 55.1% to 76.8%) vs placebo–
edaravone, 73.5% (95% CI 63.2% to 83.8%).
To further investigate this finding, an analysis of ≥2- stage 
progression in the MiToS stage revealed that most patients in 
either group did not experience this type of decline during the 
double- blind period (ie, through cycle 6) (figure 6). However, 
more rapid progression was found in the placebo–edaravone 
arm than in the edaravone–edaravone arm in the open- label 
period (log- rank test, p<0.001) (figure 6). The percentage of 
patients who experienced a ≥2- stage progression in the MiToS 
stage by the end of cycle 6 were similar: edaravone, 2.9% (95% 
CI 0.0% to 7.2%) vs placebo, 5.9% (95% CI 1.5% to 11.8%). 
By the end of cycle 12, however, there was separation in the 
Kaplan- Meier curves for a ≥2- stage progression in MiToS (log- 
rank test, p<0.001) (figure 6). Point estimates at the end of 
cycle 12 were as follows: edaravone–edaravone, 10.1% (95% CI 
4.3% to 17.4%) vs placebo–edaravone, 23.5% (95% CI 13.2% 
to 33.8%).
Concordance analysis indicated that there was overall poor 
concordance between King’s and MiToS systems in terms of 
identification of patients who underwent no progression versus 
Figure 6 Kaplan- Meier analysis of time to a ≥2- stage decline in MiToS. Kaplan- Meier curves are shown for time to a ≥2- stage decline in MiToS for 
patients in the double- blind period (blue line, edaravone; yellow line, placebo) and in the active- treatment period (blue line, edaravone–edaravone; dashed 
blue line, placebo–edaravone). Plus symbols represent patients who were censored from the analysis due to loss to follow- up (a plus symbol may represent 
more than one patient). The number of patients at risk is listed under the graph at each time point for each arm. MiToS, Milano- Torino staging.
Figure 5 Kaplan- Meier analysis of time to any decline in MiToS stage. Kaplan- Meier curves are shown for time to any decline in MiToS stage for patients 
in the double- blind period (blue line, edaravone; yellow line, placebo) and in the active- treatment period (blue line, edaravone–edaravone; dashed blue line, 
placebo–edaravone). Plus symbols represent patients who were censored from the analysis due to loss to follow- up (a plus symbol may represent more than 
one patient). The number of patients at risk is listed under the graph at each time point for each arm. MiToS, Milano- Torino staging.
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any progression (table 2). This finding confirms that the 2 staging 
systems assess different aspects of disease progression and are 
therefore complementary and largely not duplicative in terms of 
the information they provide. This difference is consistent with 
previous findings.12
Analysis of disease progression in King’s stage subgroups at 
baseline
A subgroup analysis was conducted by analysing disease progres-
sion (ie, trends in changes in ALSFRS- R score from baseline to 
cycle 6) in patients grouped according to King’s stage at baseline 
(figure 7). This analysis revealed that patients in lower King’s 
stages progressed at slower rates than patients in higher King’s 
stages. Analysis of variance indicated statistically significant 
interactions between time since enrolment and King’s stage at 
baseline and also between time since enrolment and treatment 
(p<0.001 for both).
DISCUSSION
In this retrospective analysis of data from the edaravone phase III 
trial, Study 19, both King’s ALS clinical staging system and the 
MiToS system appeared to detect differences in clinical progres-
sion between patients randomised to edaravone versus placebo. 
While the King’s system captured differences in early follow- up, 
the MiToS system appeared to capture later separation between 
treatment groups, especially in terms of a ≥2- stage progression. 
The complementary nature of the information provided by each 
staging system was further confirmed by a concordance anal-
ysis conducted on the data from these analyses. This may be 
expected, as these 2 staging systems have previously been shown 
to be complementary, with King’s staging showing greatest reso-
lution in early to mid- disease and MiToS showing higher resolu-
tion for later stages of disease.14
Post hoc analyses in this study indicated that edaravone had 
the greatest effects in slowing the transition from King’s stage 1 
to stage 2. Similar analyses of riluzole show a benefit in King’s 
stages 1 and 4 and in MiToS stage 1.8 9 The effects in prolonging 
time spent in King’s stage 1 may be particularly important to 
patients, as this is when disability is relatively low. This may also 
have implications for health economics because the earlier stages 
of ALS are associated with lower costs than later stages.7 15 16
This study highlights the potential value of ALS clinical staging 
systems as assessment tools in randomised controlled trials of 
new treatments for ALS. In that regard, the MiToS system is 
currently being used as the primary end point in an ongoing 
phase II trial in ALS17 and King’s system as a secondary end point 
in another phase II trial in ALS ( www. mirocals. eu).
One limitation of the study was its post hoc nature, since 
this analysis was based directly on the primary end point data 
from the study and simply converts ALSFRS- R score data into 
the 2 staging systems. Because findings were positive for the 
ALSFRS- R, these post hoc analyses would be biased towards 
a positive finding. Study 19, however, was not designed to 
assess effects on clinical staging and was not powered for this 
end point. Another limitation is that the correlation between 
clinical stage by examination and ALSFRS- R–estimated stage 
is 0.92.6
The key findings of this post hoc analysis are consistent 
with the proposition that ALS staging systems may be useful 
end points in clinical trials. These staging systems may be a 
novel and interesting way to deal with the problem of infor-
mative censoring that can confound results of randomised 
controlled trials and have the potential to bias their find-
ings to the null. They also may help to identify the settings 
in which particular treatments might be optimally used. The 
independent and complementary nature of the 2 systems, one 
tracking anatomical spread of disease (the King’s Clinical 
Staging System) and the other focusing on loss of function 
(the MiToS system), means they can provide different insights 
that may be particularly important in counselling patients 
on the potential benefits of therapy. Thus, clinical studies 
in ALS would be expected to benefit from including assess-
ments of clinical staging as a primary or secondary end point 
in the study. This would likely require powering the study to 
include sufficient numbers of patients at each stage, dynamic 
allocation of patients to help ensure adequate balance among 
study arms, and capturing staging data at study exit to help 
avoid censoring and improve statistical power.
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